Radium-223 in the Modern Treatment of Metastatic Castration-resistant Prostate Cancer
نویسندگان
چکیده
The objective: is to determine the current role of radium-223 in emergence new options treatment patients with metastatic castration-resistant prostate cancer.
 Materials and methods. Studies ERA-223 ALSYMPCA have identified cancer its impact on human health.
 Results. In one such study, ERA-223, it was shown that combination abiraterone did not increase survival without symptomatic skeletal events compared plus placebo. addition, a higher incidence bone fractures observed radium-223, especially receiving osteomodulators (denosumab or zoledronic acid). These results led some changes indications for use Europe more careful attention state structure An overview expert recommendations prevention events, as well consequences prolonged targeted therapy cancer, which may improve general cancer-specific survival. Radium-223 has been be an important option metastases, monitoring maintaining health factor patients. It established this category should begin androge n deprivation therapy.
 Conclusions. A review urologists, oncologists radiation Europe, who specialize advanced maintain health, cancer. Based analysis CRPD, preventive measures are recommended, side effects based clinical experience.
منابع مشابه
Radium-223 in metastatic castration resistant prostate cancer
In 2004, docetaxel was approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC). For the next several years, there was a lull in drug approvals. However, from 2010 onwards, 5 additional therapies have been approved on the basis of showing a survival benefit in phase III studies. These agents include sipuleucel-T, cabazitaxel, abiraterone, enzalutamide and (most rece...
متن کاملRadium-223 for the treatment of castration-resistant prostate cancer
The vast majority of patients with metastatic castration-resistant prostate cancer (mCRPC) develop bone metastases. Bone metastases are a source of significant morbidity and affect quality of life in these patients. Several bone-targeting agents are approved for the treatment of bone metastases in prostate cancer, including bisphosphonates, denosumab, and radiopharmaceuticals. Radium-223 is a n...
متن کاملEvolving treatment approaches for the management of metastatic castration-resistant prostate cancer – role of radium-223
Radium-223 is a first-in-class alpha particle-emitting radiopharmaceutical approved for the treatment of bone metastatic castration-resistant prostate cancer. Radium-223 is administered intravenously with no requirement for complex shielding and specifically targets areas of bone metastasis. In a randomized placebo-controlled Phase III study, treatment with radium-223 was shown to improve overa...
متن کاملWhen to initiate treatment with radium-223 in patients with metastatic castration-resistant prostate cancer.
متن کامل
Radionuclide Therapies in Prostate Cancer: Integrating Radium-223 in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
Metastatic castration-resistant prostate cancer (mCRPC) frequently metastasizes to the bone, often resulting in painful skeletal events, reduced quality of life, and reduced survival. The beta-emitting radiopharmaceuticals strontium-89 and samarium-153 alleviated pain in mCRPC patients with widespread skeletal metastases and have been associated with myelotoxicity. Radium-223, a first-in-class ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: ???????? ???????
سال: 2021
ISSN: ['2073-8005', '2311-9438']
DOI: https://doi.org/10.30841/2307-5090.4.2020.225652